{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_19148", "batch_size": 200, "batch_pos": 169, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment reports factual information about research history. No high-potency verb or metaphor.", "method": "llm_batch", "batch_id": "batch_2_13384", "batch_size": 200, "batch_pos": 140, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "The segment does not contain a moderate verb paired with explicit scale or impact information.", "method": "llm_batch", "batch_id": "batch_3_12448", "batch_size": 200, "batch_pos": 60, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_14524", "batch_size": 200, "batch_pos": 40, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "This segment reports history of research but lacks explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_16064", "batch_size": 200, "batch_pos": 35, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "No minimiser + scale contrast found.", "method": "llm_batch", "batch_id": "batch_6_18264", "batch_size": 200, "batch_pos": 197, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "No bare negation found.", "method": "llm_batch", "batch_id": "batch_7_12460", "batch_size": 200, "batch_pos": 181, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 8, "answer": "no", "rationale": "The segment describes research history, not current capabilities or preparedness.", "method": "llm_batch", "batch_id": "batch_8_11552", "batch_size": 200, "batch_pos": 35, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 9, "answer": "no", "rationale": "The segment reports history, not prices or economic metrics.", "method": "llm_batch", "batch_id": "batch_9_17972", "batch_size": 200, "batch_pos": 68, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 10, "answer": "no", "rationale": "The segment describes research history, but does not speculate about future relief or improvement.", "method": "llm_batch", "batch_id": "batch_10_14880", "batch_size": 200, "batch_pos": 35, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 11, "answer": "no", "rationale": "No quoted or attributed framing language.", "method": "llm_batch", "batch_id": "batch_11_17488", "batch_size": 200, "batch_pos": 31, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 12, "answer": "yes", "rationale": "No explicit framing cues; reports historical factual information neutrally.", "method": "llm_batch", "batch_id": "batch_12_19416", "batch_size": 200, "batch_pos": 31, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
